Biogen (HAM:IDP) Total Equity: €16,134 Mil (As of Mar. 2026)


HAM:IDP Biogen Inc HAM:IDP
73 GF Score
Price €187.44
GF Value €166.45
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biogen Total Equity?

Biogen HAM:IDP +4.05% 73 Total Equity is €16,134 Mil as of Mar. 2026. GuruFocus rates HAM:IDP with a GF Score™ of 73/100 and a GF Value™ of €166.45 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Biogen's total equity for the quarter that ended in Mar. 2026 was €16,134 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Biogen Total Equity Historical Data

* Premium members only.

The historical data trend for Biogen's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Total Equity Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,699.34 12,638.65 13,571.05 15,963.78 15,591.31

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15,705.30 15,288.68 15,512.79 15,591.31 16,133.72
HAM:IDP
73GF Score
Biogen Inc HAM:IDP
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biogen's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=25141.333-9550.026
=15,591

Biogen's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=25502.881-9369.161
=16,134

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €16,134 Mil mean?
Biogen (HAM:IDP) has a Total Equity of €16,134 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Biogen and its competitors.
Is Biogen's Total Equity too high?
Biogen's current Total Equity is €16,134 Mil. Overall, Biogen has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Total Equity compare to OGN and AMRN?
Biogen's Total Equity of €16,134 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Biogen and its competitors. Biogen's current Total Equity is €16,134 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (HAM:IDP) is currently considered Modestly Overvalued. The stock's GF Value™ is €166.45, compared to a current price of €187.44 — trading 12.6% above its estimated fair value. The current Total Equity is €16,134 Mil. Biogen's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Biogen (HAM:IDP), the current Total Equity is €16,134 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (HAM:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €187.44 is trading 12.6% above its estimated GF Value™ of €166.45. GuruFocus considers Biogen to be Modestly Overvalued.

Key valuation signals for HAM:IDP:

  • Total Equity: €16,134 Mil
  • GF Value™: €166.45 vs. price of €187.44 (12.6% above fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
73GF Score

Get the complete analysis for HAM:IDP

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€187.44
Price
€166.45
GF Value